| [Fire Fighting] Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire. | |
| [Ingestion] Seek medical attention. If individual is drowsy or unconscious, do not give anything by mouth; place individual on the left side with the head down. Contact a physician, medical facility, or poison control center for advice about whether to induce vomiting. If possible, do not leave individual unattended. | |
| [Inhalation] If symptoms develop, move individual away from exposure and into fresh air. If symptoms persist, seek medical attention. If breathing is difficult, administer oxygen. Keep person warm and quiet; seek immediate medical attention. | |
| [Skin] Flush skin with plenty of soap and water for at least 15 minutes while removing contaminated clothing and shoes. | |
| [Eyes] If symptoms develop, immediately move individual away from exposure and into fresh air. Flush eyes gently with water for at least 15 minutes while holding eyelids apart; seek immediate medical attention. | |
| [Storage] Storage location should be close to laboratory where it is to be used, so that only small amounts need to be transported. Carcinogens should be kept in only one section of storage area, explosion-proof refrigerator or freezer as required. The area should be appropriately labeled. An inventory should be kept showing the quantity of carcinogen and date it was acquired. Facilities for dispensing should be contiguous to storage area. Chemical carcinogens store below 40C, preferably between 15 and 30C, unless otherwise specified by manufacturer. Store in a tight container. Protect from freezing. | |
| [Handling] Avoid contact. Only used in a chemical hood, while using protective equipment. | |
| [Inhalation] Nausea, dizziness, headache, ataxia, blurred vision, nystagmus, and mental confusion. | |
| [Skin] Cutaneous eruptions following phenytoin therapy are common. Purple glove syndrome has been reported following intravenous phenytoin. | |
| [Eyes] Irritation. | |
| [Ingestion] Harmful fi swallowed. Can cause gastrointestinal disturbances, nausea, slurred speach. | |
| [Personal Protection] Dispensers of liquid detergent should be available. In the laboratory, gloves and protective clothing should always be worn but should not be assumed to provide full protection. Carefully fitted masks or respirators may be necessary when working with particulates or gases, and disposable plastic aprons might provide additional protection. Protective clothing should be of distinctive color, as a reminder not to be worn outside the laboratory. | |
| [Respirators] NIOSH approved respirator. | |
| [Exposure Effects] Cerebellar ataxia, nystagmus, hyperreflexia, drowsiness, lethargy, and coma may occur. Choreoathetosis and dyskinesias have been reported. CNS depression may occur more commonly in children, and ataxia may occur more commonly in adults. | |
| [Appearance] White powder. | |
| [Solubility in water] Soluble. | |
| [Melting Point] 292-299 | |
| [pKa/pKb] 8.06 (pKa) | |
| [Heat Of Vaporization] | |
| [Usage] Medication (vet), recommended for epileptic seizures in dogs. | |
| [Product Name] 5,5-Diphenylhydantoin sodium salt | |
| [Synonyms] 2,4-Imidazolidinedione, 5,5-diphenyl-, monosodium salt 5,5-Diphenyhydanthoin sodium Lepitoin sodium Minetoin Sodium 5,5-diphenyl-2,4-imidazolidinedione Sodium diphenylhydantoin | |
| [CAS] "CASEN_630-93-3.htm">630-93-3 | |
| [Formula] C15H12N2NaO2 | |
| [Molecular Weight] 275.26 | |
| [EINECS] 211-148-2 | |
| [RTECS] MU1400000 | |
| [RTECS Class] Tumorigen; Drug; Mutagen; Reproductive Effector; Human Data | |
| [Beilstein/Gmelin] 4221969 | |
| [Small spills/leaks] Evacutae area. Wear approved SCBA, rubber boots and gloves. Sweep up and place in a bag for waste disposal. Avoid reaising dust. Ventilate area. Wash spill site after pickup is complete. | |
| [Stability] Sensitive to light phenytoin a slight yellowing of the solution will not affect its potency. After being refrigerated, solution may form a precipitate which usually dissolves after being warmed to room temperature; however, do not use if the solution is not clear. | |
| [Incompatibilities] Strong oxidizing agents. | |
| [Decomposition] Oxides of carbon and nitrogen. |
Print